WASHINGTON--(BUSINESS WIRE)--The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of BioClinica, Inc. (NASDAQ: BIOC) (“BioClinica” or “the Company”), concerning the proposed acquisition of the Company by JLL Partners, Inc. Under the terms of the transaction, BioClinica shareholders would receive $7.25 per share in cash in a tender offer worth approximately $124 million.
The investigation is focused on the potential unfairness of the consideration to shareholders, the process by which the Company’s Board of Directors considered the transaction, and potential conflicts of interest among BioClinica‘s Board members.
If you are interested in discussing your rights as a BioClinica shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (202)-337-8000 or by email at firstname.lastname@example.org.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our website at www.finkelsteinthompson.com. Attorney advising. Prior results do not guarantee similar outcomes.